famotidine has been researched along with Hematologic Neoplasms in 2 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy." | 5.56 | Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis. ( Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K, 2020) |
| "When famotidine was co-administered, the concentrations decreased to 204 ng/ml and 315 ng/ml, respectively." | 2.69 | Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. ( Chiba, S; Hirai, H; Kami, M; Kanda, Y; Matsuyama, T; Mitani, K; Yazaki, Y, 1998) |
| "Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy." | 1.56 | Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis. ( Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawada, K | 1 |
| Ohta, T | 1 |
| Fukuda, H | 1 |
| Hayashi, T | 1 |
| Tanaka, K | 1 |
| Imai, T | 1 |
| Morita, Y | 1 |
| Miyamura, M | 1 |
| Kanda, Y | 1 |
| Kami, M | 1 |
| Matsuyama, T | 1 |
| Mitani, K | 1 |
| Chiba, S | 1 |
| Yazaki, Y | 1 |
| Hirai, H | 1 |
1 trial available for famotidine and Hematologic Neoplasms
| Article | Year |
|---|---|
Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Famotidine; Hematologic Neoplasms | 1998 |
1 other study available for famotidine and Hematologic Neoplasms
| Article | Year |
|---|---|
Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2020 |